The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.

Of course, weight loss supplements shouldn't be the first port of call and, before choosing to start taking any of them, it's ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

Dr. Todd Ellerin, vice chair of medicine at South Shore Health, shares the latest from the FDA about the availability of ...

And the growing popularity of a new generation of weight loss drugs has led to the use of the term “Ozempic face,” which refers to sagging, wrinkling and other facial changes experienced by some ...